Service Overview

Anti-host cell protein (HCP) antibody coverage assessment is a mandatory critical reagent characterization study for all biologic regulatory filings. This assessment characterizes the fraction of process-relevant HCPs bound by your ELISA anti-HCP polyclonal antibodies, mitigating false-negative release risks stemming from undetected HCP impurities. Our proprietary IMBS® orthogonal platform delivers two complementary testing workflows to fit early process development, method validation, and global IND/BLA submissions for mAbs, ADCs, recombinant proteins, and cell & gene therapy (CGT) products.

Regulatory Rationale: Why Coverage Testing Is Required

Global regulatory authorities — including FDA, EMA, USP, EP, ICH（Q2(R1),Q6B）— explicitly mandate full antibody coverage characterization for HCP immunoassays:

• USP <1132> Residual Host Cell Protein Measurement in Biopharmaceuticals: Requires orthogonal testing to demonstrate antibodies recognize the majority of process-derived HCPs

• EP 2.6.34 Host-Cell Protein Assays: Mandates coverage data to justify ELISA suitability for batch release

• ICH & FDA Guidance: Orthogonal mass spectrometry readouts are strongly recommended over standalone 2D Western Blot (2D-WB) to avoid underreporting coverage from denaturation artifacts

  
  

Conventional 2D-WB relies on fully denatured HCPs during separation, which fails to mimic native ELISA binding conditions and often underestimates real antibody recognition performance. Our IMBS^® technology solves this regulatory pain point via native suspension-phase immunocapture.

Proprietary IMBS^® Immunomagnetic Bead Separation Platform (Launched 2019, Huzhou Shenke)

IMBS^® covalently immobilizes anti-HCP polyclonal antibodies on magnetic microbeads for native-phase HCP capture, followed by two orthogonal analytical endpoints: IMBS^®-2D Electrophoresis and IMBS^®-LC-MS.

Standard IMBS^® Workflow

1.Covalent antibody conjugation & bead blocking to reduce non-specific binding

2.Suspension incubation with process-mimicked HCP lysate (native, non-denaturing conditions matching ELISA)

3.Stringent wash steps to remove unbound HCP impurities

4.Low-pH elution of antibody-captured HCPs

5.Downstream orthogonal analysis: 2D gel imaging or high-resolution LC-MS identification

Core IMBS^® Technical Superiorities vs Traditional 2D-WB / Resin AAE

• Native ELISA-matching binding environment – no HCP denaturation, data reflects real ELISA performance

• Superior enrichment & specificity – minimal non-specific adsorption compared to affinity resin columns

• Dual orthogonal readouts: IMBS^®-2D for visual spot coverage mapping; IMBS^®-LC-MS for digital, quantifiable whole-proteome coverage

• Proprietary SHENTEK^® AbunProteoX kit depletes high-abundance therapeutic drug substance to eliminate MS signal interference

  
  

Core Service Advantages

Regulatory & Quality System

• ISO 13485 & CNAS accredited laboratory with full in-house method validation packages for global filing

• Pre-built regulatory-ready study reports aligned with FDA/EMA IND/BLA documentation expectations

• Orthogonal dual-method design fully satisfies USP/EP orthogonal testing requirements

Technical Flexibility

• Two customizable workflows: IMBS®-2D for routine visual coverage screening; IMBS®-LC-MS for deep digital proteome characterization

• Supports all mainstream expression systems: CHO, E. coli, HEK293, Vero, Sf9, and custom cell lines

• Compatible with commercial off-the-shelf anti-HCP antibodies and client custom process-specific antibodies

Global Project Delivery Capacity

• 50+ annual HCP coverage projects covering mAb, ADC, recombinant protein, viral vector, and cell therapy pipelines

• Proven regulatory submission track record for China, US, and EU dual filings

• Dedicated regulatory scientific writing support for response to agency questions

Digital HCP Profiling with SHENTEK^® Low Abundance Enrichment Kit

Standard LC-MS HCP analysis suffers severe interference from overabundant therapeutic protein, masking low-level HCP peptides and distorting coverage results. Our proprietary SHENTEK^® AbunProteoX Low Abundance Host Residual Protein Enrichment Kit selectively depletes target drug substance, drastically boosting detectable HCP peptide groups.

Key LC-MS Deliverables

• Full inventory of all HCP species captured by your anti-HCP antibody (protein-level annotation)

• Classification of high-risk HCPs (immunogenic, protease, degradation-inducing impurities)

• Quantitative coverage percentage based on unique peptide groups

• Actionable data to guide downstream purification process optimization and process validation risk assessment

SHENTEK^® Enrichment Effect

Figure. HCP peptide group counts identified from untreated vs. AbunProteoX (SHENTEK^®) treated samples

Representative Global Client Case Studies

*Representative partial project portfolio

Sample Submission Requirements & Project Cycle

Supplementary Sample Guidance

• Samples must be representative of your full manufacturing harvest/process stream

• Frozen lysate shipped on dry ice; avoid repeated freeze-thaw cycles to prevent HCP degradation

• Provide blank null cell lysate reference material for full proteome background mapping

Standard Deliverables Upon Project Completion

• Full study report with raw chromatogram/gel imaging data

• Digital LC-MS dataset: Excel list of all antibody-recognized HCPs, peptide counts, risk classification

• Coverage percentage summary (2D spot ratio / LC-MS unique protein ratio)

• Regulatory-ready appendix for IND/BLA submission (method validation summary, IMBS platform qualification data)

• Visual 2D gel comparison maps (total HCP vs antibody-captured HCP spots)

Frequently Asked Questions（FAQ）

Q1: What typical coverage percentages do you observe across past projects?

A: Most commercial generic anti-HCP antibodies show LC-MS coverage higher than 80%, with numerous batches hitting above 90%. The majority of our custom process-specific antibodies reach ≥85% coverage via IMBS^®-LC-MS, though results differ depending on cell host and immunization design.

Q2: Is a higher coverage percentage always preferable for regulatory filings?

A: Assuming rigorous, artifact-free testing, higher coverage is universally favorable as it demonstrates broader antibody recognition of your process HCP pool. Method baseline thresholds vary by technique:

· IMBS^®-2D visual spot coverage: Industry & regulatory acceptable baseline ≥70%

· IMBS^®-LC-MS digital proteome coverage: Standard filing expectation ≥80% The higher LC-MS threshold stems from superior mass spec sensitivity and quantitative accuracy compared to gel-based 2D imaging.

Q3: What is the regulatory acceptable minimum coverage threshold for BLA/IND?

A: Regulators do not enforce an absolute hard cutoff, but global industry consensus aligned with USP <1132> guidance:

· 2D gel-based coverage: ≥70% minimum justification threshold

· Orthogonal LC-MS coverage: ≥80% preferred for full regulatory confidence Coverage below these benchmarks requires extensive scientific justification to prove no high-risk unrecognized HCPs exist in your process.

Beyond coverage percentage, regulators increasingly expect manufacturers to assess the immunogenic risk of individual HCP species — particularly those with known biological activity (e.g., proteases, cytokines) — that may evade detection.

Q4: How does IMBS® differ from traditional 2D-WB coverage testing?

A: Conventional 2D-WB fully denatures HCPs during electrophoresis, disrupting native antibody-antigen epitopes and artificially lowering measured coverage. IMBS^® performs HCP capture in native suspension matching ELISA liquid-phase conditions, delivering biologically relevant coverage data that directly correlates with your routine release assay. It also reduces non-specific background compared to static affinity resin chromatography.

Q5: Can I submit only my commercial off-the-shelf HCP antibody for coverage testing?

A: Yes, we support coverage characterization for all commercial CHO/E. coli/HEK HCP antibody kits. We recommend pairing IMBS-LC-MS orthogonal testing to identify process-specific HCPs missed by generic antibodies, a common FDA inspection observation point.

Q6: What if my program is cell & gene therapy (viral vector/cell therapy)? Are there special testing adjustments?

A: Our IMBS platform is fully optimized for CGT matrix complexity (high host cell debris, low HCP abundance). The SHENTEK^® AbunProteoX enrichment kit removes viral vector/cell product interference to recover low-level residual HCPs, and we have dedicated CGT case studies for Phase III and BLA filings.

Why Outsource Your HCP Coverage Analysis to Shenke?

Establishing a robust in-house HCP coverage characterization capability is technically feasible, but it requires significant capital investment, specialized expertise, and extensive method development time — resources that many drug development teams prefer to allocate to core pipeline activities.

The Hidden Costs of In-House Development